Patients with schizophrenia who switched from haloperidol decanoate or fluphenazine decanoate to risperidone microspheres discontinued their treatment more frequently, according to a new study published in the March issue of the Journal of Clinical Psychiatry.
Patients with schizophrenia who switched from haloperidol decanoate or fluphenazine decanoate to risperidone microspheres discontinued their treatment more frequently, according to a new study published in the March issue of the Journal of Clinical Psychiatry.
The research was led by N.H. Covell, PhD, with the New York State Psychiatric Institute. From March 2004 through March 2008, Covell and researchers conducted a randomized, controlled trial of adult outpatients with schizophrenia or schizoaffective disorder. Patients were randomly assigned to stay on their long-acting injectable medications (haloperidol decanoate or fluphenazine decanoate) or switch to risperidone microspheres. The patients were followed for 6 months, then an additional 6 months as a follow-up.
Time-to-treatment discontinuation was significantly shorter for individuals assigned to switch (31%) versus patients assigned to stay with their current medications (10%). In addition, “those randomized to switch to long-acting injectable risperidone microspheres had greater increases in body mass and prolactin,” Covell wrote.
Psychiatric Pharmacist Working to Optimize Treatment, Improve Patient Safety
December 13th 2024A conversation with Nina Vadiei, PharmD, BCPP, clinical associate professor in the Division of Pharmacotherapy at University of Texas at Austin College of Pharmacy and a clinical pharmacy specialist in psychiatry at the San Antonio State Hospital.